he U.S. Food and Drug Administration approved Roche's oral treatment for certain patients with advanced breast cancer, the regulator said Monday.The drug, giredestrant, was approved in combination with everolimus for adults with estrogen receptor-positive, HER2-negative,...
Continue reading...
[ H/T Newsmax ]